EPISODE · Jun 11, 2021 · 20 MIN

New Alzheimer Drug: Hope or Hype?

from 4sight Health Roundup (for Healthcare Executives) · host 4sight Health Roundup

We unpacked the controversies and possible market-based solutions generated by the new FDA-approved drug to treat patients with Alzheimer's Disease on today's episode of the 4sight Friday Roundup podcast. Here the week's biggest news around market-based change. David Johnson is CEO of 4sight Health. Julie Vaughan Murchinson is Partner of Transformation Capital and former CEO of Health Evolution. David Burda is News Editor and Columnist of 4sight Health. Subscribe on iTunes, Spotify, other services. Click play to listen to the 6/11/2021 Episode.

Episode metadata supplied by the publisher feed · Published Jun 11, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

New Alzheimer Drug: Hope or Hype?

0:00 20:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of 4sight Health Roundup (for Healthcare Executives)?

This episode is 20 minutes long.

When was this 4sight Health Roundup (for Healthcare Executives) episode published?

This episode was published on June 11, 2021.

Can I download this 4sight Health Roundup (for Healthcare Executives) episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!